Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Counterfeit & Under-Dosed Gray-Market Product

How prevalent mislabeling is across AAS and SARMs, and how it is actually detected

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not applicable (fraudulent/mislabeled illicit product)

Reference only. Not medical advice.

What can go wrong

The harms are: therapeutic-window problems from over- or under-dosing; unrecognized exposure to an entirely different drug (with its own toxicities, e.g., a hepatotoxic oral where a milder compound was expected); and for outright counterfeits of legitimate PDE5 drugs, documented contaminants ranging from wrong actives to industrial substances. Because the buyer believes they know what they took, clinical presentations are confounded and dangerous interactions go unanticipated.

This is something to take to a clinician. The Atlas can tell you what is known about counterfeit & under-dosed gray-market product in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Mislabeling in the gray market is not occasional, it is the baseline expectation. Van Wagoner and colleagues' 2017 JAMA analysis of 44 products sold as SARMs found only 52% contained any of the labeled SARM, the labeled dose matched in just 41%, and 39% contained a different unapproved drug (including ibutamoren, GW501516/cardarine, and SR9009). UGL steroid product shows parallel patterns in anonymous testing, under-dosing, over-dosing, and wrong-compound substitution. Detection is via independent chromatography/mass spectrometry; visual cues (holograms, packaging) are unreliable because they are the easiest thing to copy.

In one JAMA analysis of SARM products, barely half actually contained the labeled drug.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Understanding the base rate of mislabeling in gray-market product
  • Framing why label and packaging cannot be trusted

How it works

Fraud enters at two points: substitution of a cheaper or more-available compound (often upstream in the raw powder), and dose economics, under-filling saves active ingredient across thousands of units. Counterfeiters replicate packaging, holograms, and lot numbers because those are trivially copied; the one thing they cannot fake is the actual assay of the contents, which is why analytical testing is the only reliable detector.

Why packaging tells you nothing

Buyers often authenticate by hologram, scratch-code, or vendor reputation. Counterfeit operations reproduce all of these. The verifiable seizure and testing record shows that packaging sophistication correlates poorly with content accuracy, a convincing box can hold an under-dosed, substituted, or contaminated product. Only independent content analysis distinguishes real from fake.

Safety in detail

  • Base-rate mislabeling, not a rare defect
  • Wrong-compound substitution carries unexpected toxicity
  • Packaging/hologram authentication is unreliable
  • Over-dosing and under-dosing both documented

What people get wrong

  • Often said'The hologram and scratch code prove it's genuine'

    ActuallyThese are the easiest features to counterfeit and correlate poorly with actual content.

  • Often said'Under-dosed just means I wasted money'

    ActuallyUnder-dosing is a symptom of an uncontrolled process that can equally produce over-dosing, substitution, or contamination in the next unit.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

What we do not know

  • Has the mislabeling base rate changed since the 2017 SARM analysis, or held steady?
  • What share of unexplained drug-induced liver injury in gym populations reflects undisclosed compound substitution?

At a glance

JAMA SARM study (Van Wagoner, 2017)
Only 52% contained labeled SARM; dose matched in 41%
Substitution rate
39% of SARM products contained a different unapproved drug
AAS parallel
Under-, over-, and wrong-compound results common in anonymous testing
Reliable detection
HPLC/mass spectrometry, not packaging inspection

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Counterfeit & Under-Dosed Gray-Market Product. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Van Wagoner RM et al., JAMA2017

    Of 44 SARM products, 52% contained a labeled SARM, 41% matched labeled dose, 39% held a different unapproved drug

  • Anonymous UGL quantitative testingongoing

    Documented vials testing well below (and sometimes above) label, and compound substitutions